An announcement from Valbiotis SA ( (FR:ALVAL) ) is now available.
Valbiotis has disclosed its monthly update on the total number of voting rights and shares, as required by the Financial Markets Authority. This update, which includes figures for theoretical and exercisable voting rights, is crucial for stakeholders to understand potential changes in shareholder influence and compliance with regulatory thresholds. Such transparency impacts the company’s corporate governance and could influence investment decisions.
More about Valbiotis SA
Valbiotis is a French scientific research laboratory focused on developing and commercializing dietary supplements aimed at preventing and combating metabolic disorders that lead to cardiovascular diseases. The company uses a multi-target approach leveraging terrestrial and marine plants to create health nutrition products. With its foundation in 2014, Valbiotis has partnered with leading academic centers and operates three sites in France and a subsidiary in Quebec, Canada. The company engages in licensing agreements internationally and markets its products directly in France.
YTD Price Performance: -3.50%
Average Trading Volume: 1,691
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €20.83M
Find detailed analytics on ALVAL stock on TipRanks’ Stock Analysis page.